Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J O'Callaghan

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Neurology|April 17, 2013
Autosomal dominant vasovagal syncope: clinical features and linkage to chromosome 15q26Karl Martin Klein, Catherine J Bromhead, Katherine R Smith, et al.
Journal of the National Cancer Institute|August 12, 2009
Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trialNicole Mittmann, Heather-Jane Au, Dongsheng Tu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2007
End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT GroupDaniel J Sargent, Smitha Patiyil, Greg Yothers, et al.
The Oncologist|March 11, 2022
Complementary Medicine Use Amongst Patients with Metastatic Cancer Enrolled in Phase III Clinical TrialsJ Connor Wells, Aven Sidhu, Keyue Ding, et al.
Cancer|October 16, 2013
Quality of life in patients with K-RAS wild-type colorectal cancer: the CO.20 phase 3 randomized trialJolie Ringash, Heather-Jane Au, Lillian L Siu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2005
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trialsDaniel J Sargent, Harry S Wieand, Daniel G Haller, et al.
The New England Journal of Medicine|August 31, 2012
Intermittent androgen suppression for rising PSA level after radiotherapyJuanita M Crook, Christopher J O'Callaghan, Graeme Duncan, et al.
The Lancet. Gastroenterology & Hepatology|February 5, 2018
Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trialDerek J Jonker, Louise Nott, Takayuki Yoshino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2016
Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal CancerGeoffrey Liu, Dongsheng Tu, Marcia Lewis, et al.
Journal of the National Cancer Institute|January 29, 2026
Effects of a structured exercise program on motivational outcomes in patients with Colon cancerKerry S Courneya, Christopher M Booth, Janette L Vardy, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Neurology|April 17, 2013
Autosomal dominant vasovagal syncope: clinical features and linkage to chromosome 15q26Karl Martin Klein, Catherine J Bromhead, Katherine R Smith, et al.
Journal of the National Cancer Institute|August 12, 2009
Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trialNicole Mittmann, Heather-Jane Au, Dongsheng Tu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2007
End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT GroupDaniel J Sargent, Smitha Patiyil, Greg Yothers, et al.
The Oncologist|March 11, 2022
Complementary Medicine Use Amongst Patients with Metastatic Cancer Enrolled in Phase III Clinical TrialsJ Connor Wells, Aven Sidhu, Keyue Ding, et al.
Cancer|October 16, 2013
Quality of life in patients with K-RAS wild-type colorectal cancer: the CO.20 phase 3 randomized trialJolie Ringash, Heather-Jane Au, Lillian L Siu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2005
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trialsDaniel J Sargent, Harry S Wieand, Daniel G Haller, et al.
The New England Journal of Medicine|August 31, 2012
Intermittent androgen suppression for rising PSA level after radiotherapyJuanita M Crook, Christopher J O'Callaghan, Graeme Duncan, et al.
The Lancet. Gastroenterology & Hepatology|February 5, 2018
Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trialDerek J Jonker, Louise Nott, Takayuki Yoshino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2016
Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal CancerGeoffrey Liu, Dongsheng Tu, Marcia Lewis, et al.
Journal of the National Cancer Institute|January 29, 2026
Effects of a structured exercise program on motivational outcomes in patients with Colon cancerKerry S Courneya, Christopher M Booth, Janette L Vardy, et al.
Pageof 5